ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AADI Aadi Bioscience Inc

1.69
0.01 (0.60%)
15 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Aadi Bioscience Inc NASDAQ:AADI NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.01 0.60% 1.69 1.61 1.77 1.73 1.65 1.66 150,858 01:00:00

Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update

06/03/2024 1:00pm

PR Newswire (US)


Aadi Bioscience (NASDAQ:AADI)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Aadi Bioscience Charts.

Company to Host Conference Call and Webcast on March 13, 2024

LOS ANGELES, March 6, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR pathway alterations, today announced that it will host a conference call and live webcast on Wednesday, March 13, 2024 at 8:30 am ET (5:30 am PT) to report fourth quarter and full-year 2023 financial results and provide recent corporate updates.

Conference Call Information 

Participants may access a live webcast of the call on the "Investors & News" page of the Aadi Bioscience website at aadibio.com. To participate via telephone, please register in advance here: Conference Registration (vevent.com). Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the website for at least 30 days.

About Aadi Bioscience, Inc.

Aadi is a commercial-stage biopharmaceutical company focused on precision therapies for cancers to bring transformational therapies to cancer patients with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).

Aadi has also initiated PRECISION1, a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations. More information on the Company's development pipeline is available on the Aadi website at www.aadibio.com and connect with us on Twitter and LinkedIn.

Contact:
IR@aadibio.com 

(PRNewsfoto/Aadi Bioscience)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/aadi-bioscience-to-report-fourth-quarter-and-full-year-2023-results-and-corporate-update-302078967.html

SOURCE Aadi Bioscience

Copyright 2024 PR Newswire

1 Year Aadi Bioscience Chart

1 Year Aadi Bioscience Chart

1 Month Aadi Bioscience Chart

1 Month Aadi Bioscience Chart

Your Recent History